December 15th, 2015

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aurinia Pharm Ord (NQ: AUPH )

13.31 USD -1.15 (-7.95%)
Official Closing Price Updated: 7:59 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Aurinia Pharm Ord

< Previous 1 2 3 4 5 6 7 8 Next >
Aurinia Confirms Receipt of FDA End of Phase 2 Meeting Minutes
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)(TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that it has... 
From Business Wire News Releases
Aurinia Announces Appointment of Biotech Industry Leader Jeffry Randall to its Board of Directors and Audit Committee
Aurinia Announces Appointment of Biotech Industry Leader Jeffry Randall to its Board of Directors and Audit Committee 
From Business Wire News Releases
Technical Reports on Biotech Equities -- Aurinia Pharma, Threshold Pharma, Regeneron Pharma, and INSYS Therapeutics
From PR Newswire
Aurinia Highlights Renal Function Data from Global Phase IIb AURA Study of Voclosporin for Lupus Nephritis at American Society of Nephrology Kidney Week 2016
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced highlights from... 
From Business Wire News Releases
Biotech Stocks Forge Ahead With Confidence on This Week's Healthy Biotech Rally
From PR Newswire
Aurinia Highlights Speed of Remission from Global Phase IIb AURA Study of Voclosporin in Lupus Nephritis at 2016 American College of Rheumatology Annual Meeting
Aurinia Highlights Speed of Remission from Global Phase IIb AURA Study of Voclosporin in Lupus Nephritis at 2016 American College of Rheumatology Annual Meeting 
From Business Wire News Releases
Aurinia Pharmaceuticals to Present at Stifel 2016 Healthcare Conference
Aurinia Pharmaceuticals to Present at Stifel 2016 Healthcare Conference 
From Business Wire News Releases
Aurinia Establishes At-The-Market Facility
Aurinia Establishes At-The-Market Facility 
From Business Wire News Releases
Aurinia Reports Third Quarter 2016 Financial Results and Operational Highlights
Aurinia Reports Third Quarter 2016 Financial Results and Operational Highlights 
From Business Wire News Releases
IIROC Trade Resumption - AUP
From PR Newswire
IIROC Trading Halt - AUP
From PR Newswire
Aurinia Announces Plans for Single Phase III Clinical Trial for Voclosporin in the Treatment of Lupus Nephritis Following Successful Completion of End of Phase II Meeting With FDA
Aurinia Announces Plans for Single Phase III Clinical Trial for Voclosporin in the Treatment of Lupus Nephritis Following Successful Completion of End of Phase II Meeting with FDA 
From Business Wire News Releases
Aurinia Announces Acceptance of Late-Breaking Voclosporin Abstracts for Oral Presentation at Upcoming Medical Meetings
Aurinia Announces Acceptance of Late-Breaking Voclosporin Abstracts for Oral Presentation at Upcoming Medical Meetings 
From Business Wire News Releases
Research Reports Coverage on Biotech Stocks -- Merrimack Pharma, Aurinia Pharma, Aegerion Pharma, and TG Therapeutics
From PR Newswire
Aurinia Pharmaceuticals to Present at the 2016 BIO Investor Forum in San Francisco on October 18, 2016
Aurinia Pharmaceuticals to Present at the 2016 BIO Investor Forum in San Francisco on October 18, 2016 
From Business Wire News Releases
Aurinia Releases Open-Label AURION Data Demonstrating Increased Remission Rates over Time for Voclosporin in the Treatment of Lupus Nephritis
Aurinia Releases Open-Label AURION Data Demonstrating Increased Remission Rates Over Time for Voclosporin in the Treatment of Lupus Nephritis 
From Business Wire News Releases
These Top Stocks Are Trending Amid Deutsche Bank Rally
From ReleaseWire - Latest Press Releases
IIROC Trade Resumption - AUP
From PR Newswire
Aurinia Announces That Voclosporin Achieves Primary and All Pre-Specified Secondary Endpoints in Its Phase IIb AURA-LV Study for Lupus Nephritis (LN)
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”) a clinical stage biopharmaceutical company focused on the global immunology market, today announced that in addition to... 
From Business Wire News Releases
IIROC Trading Halt - AUP (all issues)
From PR Newswire
TechStockInsider.com: The Week Many Have Been Waiting For
From PR Newswire
Aurinia Pharmaceuticals to Present at the Leerink Partners Roundtable Series in New York September 28, 2016
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH /TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that its Chief Executive Officer, Charles... 
From Business Wire News Releases
Aurinia Pharmaceuticals to Host Lupus Nephritis (LN) Breakfast and Webcast on September 30th in New York
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH;TSX:AUP) today announced that it will host a Lupus Nephritis (LN) expert breakfast on Friday, September 30th from 8:00am to 9:30am EDT in New York. 
From Business Wire News Releases
Aurinia Pharmaceuticals to Present at the 2016 Rodman & Renshaw 18th Annual Global Investment Conference
Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX:AUP) today announced that its Chief Operating Officer, Michael R. Martin, will present a corporate overview of the Company at the 2016 Rodman & Renshaw... 
From Business Wire News Releases
Aurinia Pharmaceuticals Announces Voclosporin Meets Primary Endpoint in Phase IIB AURA-LV Study in Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced positive top-line... 
From Business Wire News Releases
Aurinia Reports Second Quarter 2016 Financial Results and Operational Highlights
Aurinia Reports Second Quarter 2016 Financial Results and Operational Highlights 
From Business Wire News Releases
Aurinia Pharmaceuticals to Host Lupus Nephritis Expert Breakfast and Webcast on August 4th in New York
Aurinia Pharmaceuticals to Host Lupus Nephritis Expert Breakfast and Webcast on August 4th in New York 
From Business Wire News Releases
Aurinia Establishes At-The-Market Facility
Aurinia Establishes At-the-Market Facility 
From Business Wire News Releases
Aurinia Announces Appointment of Head of Communications & Advocacy
Aurinia Announces Appointment of Head of Communications & Advocacy 
From Business Wire News Releases
Aurinia Announces 24 Week Remission Rates from the First Seven Patients in its Open Label AURION Study in Lupus Nephritis (LN)
Aurinia Announces 24 Week Remission Rates from the First Seven Patients in its Open Label AURION Study in Lupus Nephritis (LN) 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

3257 Dunmore Rd SE
Medicine Hat, AB T1B 3R2

[P] 403.527.1101
[F] 403.528.5696

Print Advertising: 403.528.5650
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2015 The Medicine Hat News, A Division of Continental Newspapers Canada Ltd.